Omalizumab Dose Step-Up and Treatment Response in Patients with Chronic Idiopathic/Spontaneous Urticaria (CIU/CSU): Results from the OPTIMA Study

Main Article Content

Wayne Gulliver
Gordon Sussman
Jacques Hebert
Charles W Lynde
Kim A Papp
William H Yang
Olivier Chambenoit
Antonio Viera
Frederica DeTakaosy
Lenka Rihakova


urticaria, omalizumab, chronic urticaria, biologic therapy


Abstract not available.


Disclosures: Study sponsored by Novartis.


Copyright 2018 SKIN


Similar Articles

You may also start an advanced similarity search for this article.

Most read articles by the same author(s)

<< < 1 2